https://www.corline.se/documents/kalender https://www.corline.se/documents/nyemission https://www.corline.se/documents/company-presentation https://www.corline.se/documents/bolagsstämmor https://www.corline.se/documents/rapporter https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2025-05-15 https://www.corline.se/documents/bolagsstämmor/protokoll-fran-arsstaemma-2024-05-15 https://www.corline.se/shared-content https://www.corline.se/privacy-policy https://www.corline.se/documents/bolagsstämmor/protokoll-fran-arsstaemma-2025-05-15 https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2024-05-15 https://www.corline.se/cookie-declaration https://www.corline.se/contact https://www.corline.se/documents/bolagsstämmor/protokoll-fran-arsstaemma-2023-05-03 https://www.corline.se/career https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2023-05-03 https://www.corline.se/products https://www.corline.se/documents/bolagsstämmor/protokoll-fran-arsstaemma-2022-05-18 https://www.corline.se/about-corline https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2022-05-18 https://www.corline.se/documents/bolagsstämmor/protokoll-fran-arsstaemma-2021-05-11 https://www.corline.se/news https://www.corline.se/products/regenerative-medicine/ https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2021-05-11 https://www.corline.se/investors https://www.corline.se/products/regenerative-medicine/chctm-soft-tissue-repair https://www.corline.se/documents/bolagsstämmor/extra-bolagsstaemma-2020-12-30 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2025 https://www.corline.se/documents https://www.corline.se/news/ https://www.corline.se/products/medical-devices/ https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2020-05-14 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-31-mars-2025 https://www.corline.se/investors/ https://www.corline.se/products/ https://www.corline.se/products/regenerative-medicine/cytoparintm-cell-therapy-diabetes-type-1 https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2019-05-07 https://www.corline.se/products/medical-devices/chs-coated-abloation-cathether https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2025 https://www.corline.se/products/medical-devices https://www.corline.se/products/chc-technology/ https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2018-05-08 https://www.corline.se/investors/finansiell-kalender https://www.corline.se/documents/rapporter/arsredovisning-2024 https://www.corline.se/products/regenerative-medicine/renaparinr-kidney-transplantation https://www.corline.se/products/chc-technology https://www.corline.se/products/medical-devices/chs-coated-stents https://www.corline.se/products/chc-technology/chc-scientific-evidence https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2024 https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2017-05-04 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-december-2024 https://www.corline.se/ https://www.corline.se/products/regenerative-medicine https://www.corline.se/investors/aktien https://www.corline.se/documents/company-presentation/company-presentation https://www.corline.se/documents/bolagsstämmor/Extra-bolagsstaemma-8:e-mars-2016 https://www.corline.se/documents/bolagsstämmor/handlingar-infoer-arsstaemma-2016-04-20 https://www.corline.se/documents/rapporter/delarsrapport-1-januari-30-juni-2024 https://www.corline.se/documents/kalender/bokslutskommunike-2023 https://www.corline.se/shared-content/shareholder-table https://www.corline.se/documents/bolagsstämmor/handlingar-infor-arsstämma-2015-03-11 https://www.corline.se/documents/bolagsstämmor/protokoll-foert-vid-aersstaemma-2015-03-11 https://www.corline.se/documents/nyemission/nyemission-2021 https://www.corline.se/investors/bolagsstämmor https://www.corline.se/documents/bolagsstämmor/Bolagsordning https://www.corline.se/documents/nyemission/nyemission-2016 https://www.corline.se/investors/nyemission https://www.corline.se/documents/rapporter/corline-biomedical-ab-delårsrapport-1-januari-31-mars-2024 https://www.corline.se/documents/bolagsstämmor/extra-bolagsstämma-2015-03-25 https://www.corline.se/documents/nyemission/nyemission-2015 https://www.corline.se/documents/rapporter/corline-biomedical-ab-arsredovisning-2023 https://www.corline.se/documents/nyemission/bolagsbeskrivning https://www.corline.se/investors/finansiella-rapporter https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-31-december-2023 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2023 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2023 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-31-mars-2023 https://www.corline.se/documents/rapporter/corline-biomedical-ab-arsredovisning-2022 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2022 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2022 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2022 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-31-mars-2022 https://www.corline.se/documents/rapporter/corline-biomedical-ab-arsredovisning-2021 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2021 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2021 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2021 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2021 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2020 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2020 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2020 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2020 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2020 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2019 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2019 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2019 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2019 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2019 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2018 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2018 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-september-2018 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2018 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2018 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2017 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2017 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-30-september-2017 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-30-juni-2017 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2017 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2016 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2016 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-30-september-2016 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-30-juni-2016 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-31-mars-2016 https://www.corline.se/documents/rapporter/corline-biomedical-arsredovisning-2015 https://www.corline.se/documents/rapporter/corline-biomedical-ab-helarsrapport-1-januari-31-december-2015 https://www.corline.se/documents/rapporter/corline-biomedical-ab-delarsrapport-1-januari-till-30-september-2015 https://www.corline.se/documents/rapporter/corline-biomedical-ab-halvarsrapport-1-januari-till-30-juni-2015 https://www.corline.se/news/corline-biomedical-genomfor-en-riktad-emission-om-23-msek https://www.corline.se/news/kardium-har-inlett-kommersialiseringen-av-globe-systemet-i-usa https://www.corline.se/news/corline-tecknar-tioarigt-licens--och-leveransavtal-med-bedomt-varde-om-cirka-2-miljarder-kronor https://www.corline.se/news/kardiums-globe-kateter-med-chs%E2%84%A2-coatning-erhaller-fda-godkannande https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2025 https://www.corline.se/news/corlines-kund-kardium-genomfor-finansiering-om-250-miljoner-usd-for-lanseringen-av-globe%C2%AE https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-mars-2025 https://www.corline.se/news/kardium-redovisar-starka-ettarsresultat-och-hog-sakerhet-i-pulsar-ide-studien https://www.corline.se/news/corline-biomedical-publicerar-arsredovisning-for-2024 https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-ab https://www.corline.se/news/corline-biomedical-ab-offentliggor-bokslutskommunik%C3%A9-for-perioden-januari-till-december-2024 https://www.corline.se/news/corlines-kund-kardium-meddelar-att-man-lamnat-in-ansokan-om-godkannande-till-fda https://www.corline.se/news/corline-biomedical-ab-omforhandlar-avtal-med-imperative-care-for-att-bredda-kundbearbetningen-inom-neurovaskulara-chs%E2%84%A2-applikationer https://www.corline.se/news/corline-biomedical-ab-offentliggor-utfall-av-riktad-emission-av-aktier https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-september-2024 https://www.corline.se/news/corline-biomedical-genomfor-en-riktad-emission-om-18-msek- https://www.corline.se/news/corline-biomedical-uppdaterar-hemsida-i-samband-med-strategiuppdateringen https://www.corline.se/news/marknadsaktorer-spar-att-snabbvaxande-pfa-segment-kommer-ta-mer-an-60-%25-av-marknaden-for-hjartflimmerbehandling-redan-2026 https://www.corline.se/news/corline-biomedical-ab-uppdaterar-sin-strategiska-plan-for-att-accelerera-vagen-fram-till-lonsamhet-och-hojer-framtida-forsaljningspotential https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2024 https://www.corline.se/news/inbjudan-till-presentation-av-corline-biomedicals-rapport-for-andra-kvartalet-2024 https://www.corline.se/news/imperative-care-sakrar-finansiering-om-150-miljoner-usd https://www.corline.se/news/kardium-sakrar-ny-finansiering-om-104-miljoner-usd-for-att-stodja-marknadslansering https://www.corline.se/news/kardium-visar-positiva-resultat-i-1-arsuppfoljningen-av-pulse-eu https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/kardium-visar-pa-utokat-kliniskt-anvandningsomrade-for-sin-chs%E2%84%A2-coatade-globe-kateter https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-mars-2024 https://www.corline.se/news/corline-biomedical-publicerar-arsredovisning-for-2023 https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/kardium-har-fardigstallt-patientrekryteringen-infor-ansokan-om-marknadsgodkannande https://www.corline.se/news/draper-vill-forbattra-ecmo-behandling-med-chs%E2%84%A2-coatad-produkt https://www.corline.se/news/corline-biomedical-uppmarksammas-i-privata-affarer https://www.corline.se/news/corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-2023 https://www.corline.se/news/imperative-care-rapporterar-framgangsrik-start-av-kliniska-forsok-med-chs%E2%84%A2-coatad-produkt https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-det-tredje-kvartalet-2023 https://www.corline.se/news/12-manadersuppfoljning-stodjer-sakerhet-och-indikerar-positiv-behandlingseffekt-av-renaparin%C2%AE https://www.corline.se/news/corline-biomedical-ab%3A-erhaller-bfarm-godkannande-att-starta-fas-2-studie https://www.corline.se/news/rattelse%3A-corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2023 https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2023 https://www.corline.se/news/corline-biomedical-ab%3A-chs%E2%84%A2-kund-i-europa-starker-finansieringen https://www.corline.se/news/corline-biomedical-ab%3A-potentiell-kund-i-usa-upphor-med-sin-verksamhet- https://www.corline.se/news/corline-biomedical-ab%3A-kardium-behandlar-forsta-usa-patienterna-i-registreringsgrundande-studie-med-chs%E2%84%A2-coatad-kateter https://www.corline.se/news/rattelse-av-pressmeddelande%3A-corline-biomedical-och-imperative-care-ingar-licens--och-leveransavtal-med-miljardpotential https://www.corline.se/news/corline-biomedical-och-imperative-care-ingar-licens--och-leveransavtal-med-miljardpotential https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-mars-2023 https://www.corline.se/news/corline-biomedical-publicerar-arsredovisning-for-2022 https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab%3A-kardium-inleder-registreringsgrundande-studie-med-chs%E2%84%A2-coatad-kateter https://www.corline.se/news/corline-biomedical-forlanger-distributionsavtal-med-agent-i-usa-for-medicinteknik https://www.corline.se/news/corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-2022 https://www.corline.se/news/corline-biomedical-ab%3A-tecknar-samarbetsavtal-for-chs%E2%84%A2-coatning-av-bypassgraft-med-ambition-att-starta-kliniska-studier-2023 https://www.corline.se/news/corline-biomedical-ab%3A-kardium-data-visar-att-chs%E2%84%A2-coatad-kateter-har-battre-sakerhetsprofil-an-konkurrerande-alternativ https://www.corline.se/news/corline-biomedical-ab%3A-lamnar-in-ny-ansokan-till-ema-om-klinisk-provning-fas-2 https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-september-2022 https://www.corline.se/news/rattelse-av-pressmeddelande%3A-corline-biomedical-ab-erhaller-godkannande-att-starta-fas-2-i-storbritannien https://www.corline.se/news/corline-biomedical-ab%3A-erhaller-godkannande-att-starta-fas-2-i-storbritannien https://www.corline.se/news/corline-biomedical-ab%3A-chs%E2%84%A2-pa-biomedevice-i-boston-28-29-september https://www.corline.se/news/corline-biomedical-ab%3A-kliniska-data-fran-renapair-01-publiceras-i-transplantation-direct https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2022 https://www.corline.se/news/corline-biomedical-ab%3Atillaggsavtal-med-kardium-sakrar-finansieringen-under-utvecklingsfasen https://www.corline.se/news/corline-biomedical-ab%3A-europeiska-patentmyndigheten-avser-godkanna-ytterligare-renaparin-patent- https://www.corline.se/news/corline-biomedical-ab-tecknar-avtal-med-cro-leverantor-for-fas-2-studie-inom-njurtransplantation-och-adderar-leverantor-av-lakemedelssubstans https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-det-forsta-kvartalet-2022 https://www.corline.se/news/corline-biomedical-ab-presenterar-pa-naventus-healthcare-summit-i-stockholm-den-10-maj https://www.corline.se/news/corline-biomedical-ab-publicerar-arsredovisning-for-2021 https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-(publ) https://www.corline.se/news/corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-2021 https://www.corline.se/news/corline-biomedical-ab%3A-kardium-rapporterar-om-forsta-behandlade-patient-i-klinisk-studie-i-tjeckien https://www.corline.se/news/corline-biomedical-ab%3A-samarbetspartner-i-kliniska-forsok-med-chs%E2%84%A2-coatade-produkter-i-bade-nordamerika-och-europa https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-det-tredje-kvartalet-2021 https://www.corline.se/news/corline-biomedical-ab%3A-imperative-care-tecknar-avtal-om-produktleveranser-for-7%2C5-msek https://www.corline.se/news/corline-biomedical-ab%3A-uppdatering-av-affarsverksamhet-och-utvecklingsprojekt https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-perioden-januari-till-juni-2021 https://www.corline.se/news/corline-biomedical-ab%3A-ingar-term-sheet-avseende-ytterligare-en-medicinteknisk-applikation-i-usa https://www.corline.se/news/imperative-care-annonserar-finansiering-om-260-musd https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-det-forsta-kvartalet-2021 https://www.corline.se/news/corline-biomedical-arsredovisning-for-2020 https://www.corline.se/news/corline-biomedical-ab-kallar-till-arsstamma-2021 https://www.corline.se/news/corline-biomedical-ab-har-genomfort-en-riktad-emission-om-cirka-35%2C5-miljoner-kronor https://www.corline.se/news/corline-biomedical-ab-avser-att-genomfora-en-riktad-nyemission https://www.corline.se/news/corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-2020 https://www.corline.se/news/corline-biomedical-forlanger-distributionsavtal-med-agent-i-usa-for-medicinteknik https://www.corline.se/news/kardium-annonserar-finansiering-om-115-musd https://www.corline.se/news/corline-biomedicals-foretradesemission-overtecknad-med-342-procent https://www.corline.se/news/corline-biomedical-ab%3A-kommunik%C3%A9-fran-extra-bolagsstamma https://www.corline.se/news/kallelse-till-extra-bolagsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-har-beslutat-om-en-fullt-ut-garanterad-foretradesemission-om-15-msek https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-januari-till-september-2020 https://www.corline.se/news/magnus-nilsson-forstarker-styrelsen-i-corline https://www.corline.se/news/corline-ingar-avtal-med-amerikanskt-bolag-inom-strokevard https://www.corline.se/news/corline-lamnar-in-studiedata-till-lakemedelsverket-och-preciserar-studiedesign-for-klinisk-fas-2 https://www.corline.se/news/corline-ingar-licens--och-leveransavtal-inom-medicinteknik https://www.corline.se/news/corline-biomedical-ab-offentliggor-halvarsrapport-for-det-forsta-halvaret-2020 https://www.corline.se/news/corline-biomedical-ab%3A-europeiska-patentmyndigheten-avser-godkanna-renaparin-patent- https://www.corline.se/news/corlines-lakemedelskandidat-renaparin%C2%AE-uppvisar-god-sakerhetsprofil-i-forsta-studien-pa-patienter https://www.corline.se/news/corline-biomedical-ab-presenterar-pa-redeyes-growth-day-2020 https://www.corline.se/news/corline-biomedical-ab-presenterar-pa-redeyes-temaevent-orphan-drugs https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-det-forsta-kvartalet-2020 https://www.corline.se/news/corline-biomedical-ab-publicerar-arsredovisning-for-2019 https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/aven-europeiska-lakemedelsmyndigheten-positiv-till-corlines-planerade-fas-2-studie https://www.corline.se/news/corline-biomedical-ab-har-fardigstallt-patientrekryteringen-i-fas-1-studien https://www.corline.se/news/corline-biomedical-ab-valjer-redeye-ab-som-certified-adviser https://www.corline.se/news/corline-biomedical-ab-publicerar-uppdaterad-bokslutskommunik%C3%A9-for-2019 https://www.corline.se/news/corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-2019 https://www.corline.se/news/corline-biomedical-ab%3A-valjer-tillverkare-av-lakemedelssubstans-for-fas-2-studier https://www.corline.se/news/corline-biomedical-ab%3A-renaparin%C2%AE-presenteras-for-american-society-of-transplantation https://www.corline.se/news/corline-biomedical-ab%3A-okad-takt-i-njurtransplantationsstudien https://www.corline.se/news/corline-biomedical-ab%3A-fda-ger-positiv-feedback-angaende-bolagets-planerade-fas-2-studie https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-det-tredje-kvartalet-2019 https://www.corline.se/news/corline-biomedical-ab%3A-inga-negativa-sakerhetsfynd-i-renapair-01-efter-fyra-patienter-%E2%80%93-sahlgrenska-och-karolinska-adderas-till-studien https://www.corline.se/news/corline-biomedical-ab%3A-fyra-forsta-patienterna-inkluderade-i-njurtransplantationsstudien https://www.corline.se/news/corline-biomedical-ab-inleder-samarbete-med-uhn-toronto-for-utveckling-av-renaparin%C2%AE-for-lungtransplantation https://www.corline.se/news/corline-biomedical-ab-publicerar-halvarsrapport-for-det-forsta-halvaret-2019 https://www.corline.se/news/corline-biomedical-ab-presenterar-pa-pareto-securities-health-care-conference-den-5%3Ae-september-2019 https://www.corline.se/news/corline-biomedical-ab%3A-byte-av-certified-adviser https://www.corline.se/news/corline-biomedical-ab%3A-andring-av-tidigare-offentliggjord-nyemission https://www.corline.se/news/corline-biomedical-ab%3A-fortydligande-av-status-for-patientrekrytering-i-renaparin%C2%AE-studie https://www.corline.se/news/corline-biomedical-ab%3A-riktad-nyemission-om-ca-14-msek https://www.corline.se/news/corline-biomedical-ab-offentliggor-delarsrapport-for-det-forsta-kvartalet-2019 https://www.corline.se/news/corline-biomedical-ab%3A-presentera-pa-smabolagsdagen-den-3-juni-i-stockholm https://www.corline.se/news/corline-biomedical-ab%3A-will-present-at-investor-event-hosted-by-aktiespararna-on-june-3rd-in-stockholm https://www.corline.se/news/corline-biomedical-ab%3A-lakemedelsverket-godkanner-patientrekrytering-pa-sahlgrenska https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab%3Aarsredovisning-2018 https://www.corline.se/news/corline-biomedical-ab%3A-kallelse-till-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-presenterar-pa-svd-borsplus-temadag-dubblare https://www.corline.se/news/corline-biomedical-ab-offentliggor-bokslutskommunik%C3%A9-for-rakenskapsaret-2018 https://www.corline.se/news/corline-biomedical-ab%3A-forsta-patient-doserad-med-renaparin%C2%AE https://www.corline.se/news/corline-biomedical-ab%3A-rekryterar-lars-olsson-som-head-of-cmc https://www.corline.se/news/corline-biomedical-ab%3A-patientrekrytering-startar-i-renaparin-studie https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-forsta-nio-manaderna-2018 https://www.corline.se/news/corline-biomedical-ab%3A-renaparin-studie-publiceras-i-vetenskaplig-tidskrift https://www.corline.se/news/corline-biomedical-ab-publicerar-halvarsrapport-for-forsta-halvaret-2018 https://www.corline.se/news/corline-biomedical-ab%3A-lakemedelsverket-ger-tillstand-till-klinisk-provning-av-renaparin%C2%AE https://www.corline.se/news/corline-biomedical-ab%3A-corline-erhaller-andra-utbetalningen-fran-eu-kommissionen https://www.corline.se/news/corline-biomedical-ab%3A-erhaller-patentgodkannande-i-kina https://www.corline.se/news/corline-biomedical-ab%3A-riktad-nyemission-och-fullt-utnyttjat-optionsprogram https://www.corline.se/news/corline-biomedical-ab%3A-ansokan-om-klinisk-provning-av-renaparin%C2%AE-inlamnad https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-forsta-kvartalet-2018---rapport-inkluderad-som-pdf https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-forsta-kvartalet-2018---rapport-inkluderad-som-pdf https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-forsta-kvartalet-2018 https://www.corline.se/news/kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab%3A-ingar-term-sheet-avseende-medicinteknisk-applikation https://www.corline.se/news/kallelse-till-arsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-biomedical-ab%3A-scientific-reports-publicerar-resultat-fran-renaparin-utvecklingen https://www.corline.se/news/corline-biomedical-ab%3A-ytterligare-vinnovaanslag-till-nya-indikationer-for-renaparin https://www.corline.se/news/corline-biomedical-ab%3A-publicerar-bokslutskommunik%C3%A9-for-2017 https://www.corline.se/news/corline-biomedical-ab%3A-anstaller-professor-gunnar-tufveson-pa-nyinrattad-tjanst-som-chief-medical-officer https://www.corline.se/news/corline-biomedical-ab%3A-klinisk-fas-1-studie-med-renaparin-godkanns-av-etikprovningsnamnden https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-januari---september-2017 https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-januari---september-2017 https://www.corline.se/news/corline-biomedical-ab%3A-renaparin-utvecklas-for-nya-indikationsomraden https://www.corline.se/news/corline-biomedical-ab%3A-corline-utokar-scientific-advisory-board https://www.corline.se/news/corline-biomedical-ab%3A-corline-genomfor-riktad-nyemission-om-cirka-15-msek https://www.corline.se/news/corline-biomedical-ab%3A-corline-genomfor-riktad-nyemission-om-cirka-15-msek https://www.corline.se/news/corline-biomedical-ab%3A-publicerar-halvarsrapport-for-perioden-januari---juni-2017 https://www.corline.se/news/corline-biomedical-ab%3A-publicerar-halvarsrapport-for-perioden-januari---juni-2017 https://www.corline.se/news/corline-biomedical-ab%3A-notice-of-allowance-for-renaparin-patent-i-usa- https://www.corline.se/news/corline-biomedical-ab%3Atecknar-avsiktsforklaring-med-university-of-alberta-i-kanada-avseende-bolagets-kliniska-studie-inom-diabetes-typ-1 https://www.corline.se/news/corline-biomedical-ab%3Atecknar-avsiktsforklaring-med-university-of-alberta-i-kanada-avseende-bolagets-kliniska-studie-inom-diabetes-typ-1 https://www.corline.se/news/corline-biomedical-ab%3A-tecknar-avsiktsforklaring-med-oxford-university-avseende-bolagets-kliniska-studie-inom-diabetes-typ-1- https://www.corline.se/news/corline-biomedical-ab%3A-deltar-som-sponsor-vid-ipita-2017-i-oxford https://www.corline.se/news/corline-biomedical-ab%3A-uppdatering-av-status-i-utvecklingsprojekten https://www.corline.se/news/corline-biomedical-ab%3A-deltar-pa-erik-penser-banks-bolagsdag-23-maj-2017 https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-januari-till-mars-2017 https://www.corline.se/news/corline-biomedical-ab%3A-stammokommunik%C3%A9-fran-arsstamma https://www.corline.se/news/corline-biomedical-ab%3A-corline-erhaller-sarlakemedelsstatus-i-usa- https://www.corline.se/news/corline-biomedical-ab%3A-kallelse-till-arsstamma https://www.corline.se/news/corline-biomedical-ab%3A-ytterligare-kompetens-och-natverk-tillfors-styrelsen https://www.corline.se/news/corline-biomedical-ab%3A-renaparin%C2%AE-visar-god-sakerhetmarginal https://www.corline.se/news/corline-biomedical-ab%3A-npitg-kraver-ytterligare-preklinisk-data-for-cytoparin https://www.corline.se/news/corline-biomedical-ab%3A-corline-biomedical-ab-publicerar-bokslutskommunik%C3%A9-for-januari---december-2016 https://www.corline.se/news/corline-biomedical-ab%3A-corline-har-hallit-mote-med-representanter-for-npitg%2Fscandiatransplant https://www.corline.se/news/corline-biomedical-ab%3A-npitg%2Fscandiatransplant-vill-granska-den-prekliniska-datan-fore-uppstart-av-cytoparin(tm)-studien https://www.corline.se/news/corline-biomedical-ab%3A-avtal-undertecknat-for-eu-anslaget-som-ger-100-%25-finansieringsgrad-for-renaparin%C2%AE-projektet https://www.corline.se/news/corline-biomedical-ab%3A-datum-for-publicering-av-bokslutskommunik%C3%A9 https://www.corline.se/news/corline-biomedical-ab%3A-renaparin%C2%AE-ger-battre-njurfunktion-i-proof-of-priniciple-studie https://www.corline.se/news/corline-biomedical-ab%3A-erhaller-over-23-miljoner-sek-i-anslag-fran-eu-kommissionen https://www.corline.se/news/corline-biomedical-ab-publicerar-delarsrapport-for-januari---september-2016 https://www.corline.se/news/corline-biomedical-ab%3A-corline-biomedical-ab-publicerar-delarsrapport-for-januari---september-2016 https://www.corline.se/news/corline-biomedical-ab%3A-corline-kommer-att-presentera-pa-nordic-american-life-science-conference-2016 https://www.corline.se/news/corline-biomedical-ab%3A-presenterar-pa-french-swedish-life-science-day-2016 https://www.corline.se/news/corline-biomedical-ab%3A-tecknar-kontrakt-om-gmp-produktion-och-toxikologistudie-for-renaparin%C2%AE https://www.corline.se/news/corline-biomedical-ab%3A-corline-biomedical-ab-publicerar-delarsrapport-for-januari---juni-2016 https://www.corline.se/news/corline-biomedical-ab%3A-lakemedelsverket-beviljar-tillstand-att-genomfora-klinisk-lakemedelsstudie-av-cytoparin https://www.corline.se/news/corline-biomedical-ab%3A-renaparin%C2%AE-erhaller-1-msek-i-anslag-fran-vinnova https://www.corline.se/news/corline-biomedical-ab%3A-corline-biomedical-ab-publicerar-delarsrapport-for-januari---mars-2016 https://www.corline.se/news/corline-biomedical-ab%3A-etikprovningsnamnden-ger-godkannande-till-klinisk-studie-for-cytoparin https://www.corline.se/news/corline-biomedical-ab%3A-kommunik%C3%A9-fran-arsstamma-i-corline-biomedical-ab https://www.corline.se/news/corline-biomedical-ab%3A-djurstudier-visar-att-renaparin%C2%AE-forbattrar-njurfunktion-efter-transplantation https://www.corline.se/news/corline-biomedical-ab%3A-registrerar-varumarket-renaparin%C2%AE-i-eu https://www.corline.se/news/foretradesemission-i-corline-biomedical-ab-overtecknad https://www.corline.se/news/corline-biomedical-ab%3A-arsredovisning-for-2015-tillganglig https://www.corline.se/news/corline-biomedical-ab%3A-kallelse-till-arsstamma-i-corline-biomedical-ab-(publ)- https://www.corline.se/news/corline-biomedical-ab%3A-andrat-datum-for-arsstamma https://www.corline.se/news/corline-biomedical-ab%3A-kommunik%C3%A9-fran-extra-bolagsstamma- https://www.corline.se/news/corline-biomedical-ab%3A-investerartraff-med-corline-pa-erik-penser-bank-infor-nyemissionen https://www.corline.se/news/corline-biomedical-ab%3A-offentliggor-prospekt-avseende-foretradesemission https://www.corline.se/news/corline-biomedical-ab%3A-foreslar-ytterligare-forstarkning-av-styrelsen- https://www.corline.se/news/corline-biomedical-ab%3A-helarsapport-for-perioden-januari---december-2015-tillganglig https://www.corline.se/news/corline-biomedical-ab%3A-kallelse-till-extra-bolagsstamma-i-corline-biomedical-ab-(publ) https://www.corline.se/news/corline-foreslar-beslut-om-foretradesemission-om-25%2C5-msek https://www.corline.se/news/corline-biomedical-ab%3A-inga-patent-hindrar-renaparin https://www.corline.se/news/corline-biomedical-ab%3A-rekryterar-senior-projektledare-for-att-accelerera-utvecklingen-av-renaparin https://www.corline.se/news/corline-biomedical-ab%3A-delarsrapport-for-perioden-januari---september-2015-tillganglig https://www.corline.se/news/corline-biomedical-ab%3A-kraftigt-okad-marknadspotential-for-renaparin https://www.corline.se/news/corline-biomedical-ab%3A-preklinisk-studie-avseende-renaparin(tm)-visar-mycket-hog-tolerabilitet https://www.corline.se/news/corline-biomedical-ab-ansoker-om-orphan-drug-status-for-renaparin-hos-fda https://www.corline.se/news/corline-biomedical-ab-tecknar-avtal-om-likviditetsgaranti-i-handeln-med-bolagets-aktie https://www.corline.se/news/corline-biomedical-ab%3A-ansoker-om-att-prova-cytoparin-som-lakemedel-i-den-kommande-kliniska-studien https://www.corline.se/news/corline-biomedical-ab%3A-halvarsrapport-1-januari-till-30-juni-2015 https://www.corline.se/news/corline-biomedical-ab%3A-ema-advice-for-renaparin-i-linje-med-nuvarande-utvecklingsplan https://www.corline.se/news/corline-biomedical-ab%3A-nybildade-dotterbolaget-corline-pharma-ab-ingar-avtal-med-astrazeneca-bioventurehub- https://www.corline.se/news/corline-biomedical-ab%3A-nybildade-dotterbolaget-corline-pharma-ab-ingar-avtal-med-astrazeneca-bioventurehub https://www.corline.se/news/corline-biomedical-ab%3A-forsta-dag-for-handel-pa-nasdaq-first-north-i-stockholm https://www.corline.se/news/corline-biomedical-ab%3A-teckning-av-optioner-av-serie-2015%2F2018 https://www.corline.se/news/corline-biomedical-ab%3A-godkant-for-listning-pa-nasdaq-first-north-i-stockholm https://www.corline.se/news/corline-biomedical-ab%3A-tillfors-drygt-850-nya-agare-i-en-flerfaldigt-overtecknad-nyemission-infor-planerad-listning-pa-nasdaq-first-north